| Literature DB >> 32763164 |
Nick van Gastel1, Jessica B Spinelli2, Azeem Sharda1, Amir Schajnovitz1, Ninib Baryawno3, Catherine Rhee1, Toshihiko Oki1, Eliane Grace1, Heather J Soled1, Jelena Milosevic4, David B Sykes4, Peggy P Hsu5, Matthew G Vander Heiden6, Charles Vidoudez7, Sunia A Trauger7, Marcia C Haigis2, David T Scadden8.
Abstract
Cancer relapse begins when malignant cells pass through the extreme metabolic bottleneck of stress from chemotherapy and the byproducts of the massive cell death in the surrounding region. In acute myeloid leukemia, complete remissions are common, but few are cured. We tracked leukemia cells in vivo, defined the moment of maximal response following chemotherapy, captured persisting cells, and conducted unbiased metabolomics, revealing a metabolite profile distinct from the pre-chemo growth or post-chemo relapse phase. Persisting cells used glutamine in a distinctive manner, preferentially fueling pyrimidine and glutathione generation, but not the mitochondrial tricarboxylic acid cycle. Notably, malignant cell pyrimidine synthesis also required aspartate provided by specific bone marrow stromal cells. Blunting glutamine metabolism or pyrimidine synthesis selected against residual leukemia-initiating cells and improved survival in leukemia mouse models and patient-derived xenografts. We propose that timed cell-intrinsic or niche-focused metabolic disruption can exploit a transient vulnerability and induce metabolic collapse in cancer cells to overcome chemoresistance.Entities:
Keywords: acute myeloid leukemia; aspartate; bone marrow niche; cell metabolism; chemotherapy; glutamine; mouse models; patient-derived xenografts; pyrimidine synthesis; tumor microenvironment
Year: 2020 PMID: 32763164 DOI: 10.1016/j.cmet.2020.07.009
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287